ReviewDiabetology & metabolic syndrome2025
The role of myocardial fibrosis in the diabetic cardiomyopathy.
Review in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- MicroRNAs in type 2 diabetes mellitus and its cardiovascular complications: mechanistic insights and translational potential.Internal and emergency medicine · 2026Review
- Integrative insights into fatty acid metabolism in diabetic cardiomyopathy: From molecular mechanisms to therapeutic strategies.iScience · 2026Review
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Diabetes-Related Alterations in Vectorcardiographic Repolarization Geometry: Insights from Physiological and Machine-Learning Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Integrated Multi-Omics Analysis Identifies PDK4 and ACOT1 as Metabolic Hub Genes Associated With Myocardial Fibrosis in Diabetic Cardiomyopathy.Journal of diabetes research · 2026Article
- Higenamine Hydrochloride Ameliorates Diabetic Cardiomyopathy Through RhoA/MEK/ERK Pathway.Inflammation · 2025Article
- Review
- Mechanisms of circular RNAs in diabetic cardiomyopathy: biological characteristics and clinical prospects.Frontiers in genetics · 2025Review
- Role of gut microbiota and its metabolites in diabetic cardiomyopathy: from pathogenesis to interventions.Frontiers in cardiovascular medicine · 2025Review
- Diabetic cardiomyopathy and COVID-19: intersecting pathways and amplified cardiovascular risk.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic cardiomyopathy (DCM), a main cardiovascular complication of diabetes mellitus, can eventually develop into heart failure and seriously affect the prognosis of diabetic patients. Myocardial fibrosis (MF) is the main factor causing ventricular wall stiffness and heart failure in DCM. Early control of MF in DCM is of great significance to prevent or postpone the progression of DCM to heart failure. In this review, we systematically analyzed the relevant studies on diabetic MF in recent years, explored the formation mechanism of MF in the pathological process of DCM, and summarized and analyzed in detail the current studies with antifibrotic treatment for DCM, so as to provide guidance for the development of prevention and treatment strategies for MF in DCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.